Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000598423 | SCV000705010 | uncertain significance | not provided | 2017-01-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000598423 | SCV001021343 | benign | not provided | 2024-10-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000598423 | SCV001334558 | uncertain significance | not provided | 2021-11-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000598423 | SCV001995072 | uncertain significance | not provided | 2023-08-22 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Prevention |
RCV004543355 | SCV004764915 | uncertain significance | SOX10-related disorder | 2024-02-08 | no assertion criteria provided | clinical testing | The SOX10 c.574G>A variant is predicted to result in the amino acid substitution p.Gly192Ser. To our knowledge, this variant has not been reported in literature. This variant has been reported at a frequency of ~0.022% in individuals of European (Non-Finnish) origin in a large population database and has been reported in ClinVar with conflicting interpretations (https://www.ncbi.nlm.nih.gov/clinvar/variation/499498/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |